Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease.

Evidence span

Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease.

From Fertan E et al. 2025, Alzheimer's & dementia : the journal of the Alzheimer's Association

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

Homo sapiens

Conditions

Brain; Humans; Alzheimer Disease; Antibodies, Monoclonal; Amyloid beta-Peptides — Alzheimer's & dementia : the journal of the Alzheimer's Association 2025

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required